Get started
Author

Shingo Shoji

Observed institution: Chordia Therapeutics Inc. (Japan)
ORCID: 0009-0006-8758-2243
Observed ORCID: 0009-0006-8758-2243
OpenAlex ID: A5136358785
Data from Phase I Study of Rogocekib in Patients with Advanced, Relapsed, or Refractory Malignant Solid Tumors
2026 · Jun Sato, Yuki Katsuya, et al.
Table 2 from Phase I Study of Rogocekib in Patients with Advanced, Relapsed, or Refractory Malignant Solid Tumors
2026 · Jun Sato, Yuki Katsuya, et al.
Figure S5 from Phase I Study of Rogocekib in Patients with Advanced, Relapsed, or Refractory Malignant Solid Tumors
2026 · Jun Sato, Yuki Katsuya, et al.
Table S3 from Phase I Study of Rogocekib in Patients with Advanced, Relapsed, or Refractory Malignant Solid Tumors
2026 · Jun Sato, Yuki Katsuya, et al.
Figure S1 from Phase I Study of Rogocekib in Patients with Advanced, Relapsed, or Refractory Malignant Solid Tumors
2026 · Jun Sato, Yuki Katsuya, et al.
Table S4 from Phase I Study of Rogocekib in Patients with Advanced, Relapsed, or Refractory Malignant Solid Tumors
2026 · Jun Sato, Yuki Katsuya, et al.
Figure 2 from Phase I Study of Rogocekib in Patients with Advanced, Relapsed, or Refractory Malignant Solid Tumors
2026 · Jun Sato, Yuki Katsuya, et al.
Table S2 from Phase I Study of Rogocekib in Patients with Advanced, Relapsed, or Refractory Malignant Solid Tumors
2026 · Jun Sato, Yuki Katsuya, et al.
Table S6 from Phase I Study of Rogocekib in Patients with Advanced, Relapsed, or Refractory Malignant Solid Tumors
2026 · Jun Sato, Yuki Katsuya, et al.
Figure S2 from Phase I Study of Rogocekib in Patients with Advanced, Relapsed, or Refractory Malignant Solid Tumors
2026 · Jun Sato, Yuki Katsuya, et al.
Figure S6 from Phase I Study of Rogocekib in Patients with Advanced, Relapsed, or Refractory Malignant Solid Tumors
2026 · Jun Sato, Yuki Katsuya, et al.
Table S5 from Phase I Study of Rogocekib in Patients with Advanced, Relapsed, or Refractory Malignant Solid Tumors
2026 · Jun Sato, Yuki Katsuya, et al.
Table 3 from Phase I Study of Rogocekib in Patients with Advanced, Relapsed, or Refractory Malignant Solid Tumors
2026 · Jun Sato, Yuki Katsuya, et al.
Figure S4 from Phase I Study of Rogocekib in Patients with Advanced, Relapsed, or Refractory Malignant Solid Tumors
2026 · Jun Sato, Yuki Katsuya, et al.
Table S7 from Phase I Study of Rogocekib in Patients with Advanced, Relapsed, or Refractory Malignant Solid Tumors
2026 · Jun Sato, Yuki Katsuya, et al.
Figure S3 from Phase I Study of Rogocekib in Patients with Advanced, Relapsed, or Refractory Malignant Solid Tumors
2026 · Jun Sato, Yuki Katsuya, et al.
Table 4 from Phase I Study of Rogocekib in Patients with Advanced, Relapsed, or Refractory Malignant Solid Tumors
2026 · Jun Sato, Yuki Katsuya, et al.
Table 1 from Phase I Study of Rogocekib in Patients with Advanced, Relapsed, or Refractory Malignant Solid Tumors
2026 · Jun Sato, Yuki Katsuya, et al.
Figure S7 from Phase I Study of Rogocekib in Patients with Advanced, Relapsed, or Refractory Malignant Solid Tumors
2026 · Jun Sato, Yuki Katsuya, et al.
Table S1 from Phase I Study of Rogocekib in Patients with Advanced, Relapsed, or Refractory Malignant Solid Tumors
2026 · Jun Sato, Yuki Katsuya, et al.
Figure 1 from Phase I Study of Rogocekib in Patients with Advanced, Relapsed, or Refractory Malignant Solid Tumors
2026 · Jun Sato, Yuki Katsuya, et al.
Phase I Study of Rogocekib in Patients with Advanced, Relapsed, or Refractory Malignant Solid Tumors
2026 · Jun Sato, Yuki Katsuya, et al. · Clinical Cancer Research
Works count: 22
Citation count:
H-index:
I10-index:
Year
Topic
Type